MCM
PTCT icon

Moore Capital Management’s PTC Therapeutics PTCT Stock Holding History

Moore Capital Management’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-30,500
Closed -$684K – 521
2023
Q3 		$684K Buy
+30,500
New +$1.13M 0.01% 322
2015
Q3 		– Sell
-50,000
Closed -$2.41M – 378
2015
Q2 		$2.41M Buy
+50,000
New +$2.92M 0.05% 294

Other funds holding PTCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Moore Capital Management's PTCT Position: Q2 2026 in Review

Moore Capital Management increased its PTC Therapeutics (PTCT) stake by 69% in Q2 2026, buying an estimated $2.23M and bringing the position to 75,588 shares worth $6.17M. The position accounts for 0.09% of the portfolio, ranked #193.

Moore Capital Management first reported a position in PTCT in Q1 2015 and has held it in 32 quarters since. The position peaked at $10.1M in Q4 2019. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

  • Moore Capital Management held 75,588 shares of PTC Therapeutics worth $6.17M as of Q2 2026.
  • Moore Capital Management bought 30,894 PTC Therapeutics shares in Q2 2026, an estimated $2.23M.
  • PTC Therapeutics made up 0.09% of Moore Capital Management's portfolio in Q2 2026, its #193 holding.
  • Moore Capital Management first reported a position in PTC Therapeutics in Q1 2015 and has held it in 32 quarters since.
  • Moore Capital Management's PTC Therapeutics position peaked at $10.1M in Q4 2019.
  • 382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Moore Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.